Honasa Consumer Ltd

- The transcript does not mention any current or planned fundraising through debt or equity. - There is no discussion of raising capital in the Q2 FY26 earnings call or management commentary. - The focus is primarily on organic growth, brand building, distribution expansion, and strategic minority investments (e.g., 25% stake in oral care brand Fang). - Management shows interest in potentially increasing ownership stakes in minority investments if the brands perform well, but no explicit plans to raise external funds were shared. - Emphasis is on operational efficiencies, margin improvement, and optimizing existing investments rather than external fundraising.

- Honasa Consumer is actively investing in building new brands, focusing on mega brand creation opportunities in India driven by a new generation of consumers. - They have a dedicated function called the "brand factory" to cultivate and scale new brands, with openness to participation or M&A when internal bandwidth is insufficient. - An investment was made in Fang, an early-stage oral care brand where Honasa holds a 25% stake, with options to increase stake in the future based on performance. - The company emphasizes capital-efficient growth by building own brands rather than only acquiring. - No explicit mention of large-scale current or future capex; focus seems more on strategic brand investments and supply chain improvements. - Transitioning distribution from super-stockists to direct distributors is an ongoing strategic investment to improve GT reach.

- Mamaearth is back to growth with an objective of high single-digit growth in the next quarter and aims to reach double-digit growth by Q4, maintaining this into next year. - Core categories' contribution expected to rise from 75% to around 84-85% over the next 4-6 quarters, driving strong share ownership. - Derma Co has strong growth potential with plans to build moisturizer and shampoo categories, targeting INR1,000+ crores in 1-2 years. - Quick commerce channel is rapidly growing, currently about 10% of revenues, with healthy economics and fastest-growing channel. - Total secondary sales growing well with 35% Y-o-Y increase in direct outlet billings; brand availability expanded to over 250,000 retail outlets. - Focus on offline expansion for brands like Derma Co, now INR100+ crores in offline run rate. - New brands like Lumineve in build phase targeting large long-term opportunity. - Overall, sustained growth backed by focus on core categories, offline distribution, and channel expansion.

- Honasa Consumer expects to maintain or improve EBITDA margin around the current 7-8% range with a target to unlock 50 to 100 basis points of operating margin annually through procurement efficiencies, marketing efficiency, and product mix improvements. - Mamaearth is projected to show high single-digit growth in the near term, aiming for double-digit growth by Q4 FY26 and maintaining that pace into FY27. - Derma Co is targeting expanding into moisturizer and hair categories to reach INR1,000+ crores net sales in 1-2 years with strong profitability (high single-digit EBITDA profile currently). - The company anticipates continued strong like-for-like revenue growth (~22%) supported by core categories growing faster than the company average. - Long term, Honasa plans to participate in large opportunities like the $4 billion prestige skincare and $700 million oral care markets, supporting earnings growth over the next decade. - Overall, operating leverage and scale benefits are expected to contribute to margin expansion and profitability improvement.

The transcript from Honasa Consumer Limited's Q2 FY26 earnings call does not provide specific details on current or expected orderbook or pending orders. Key points from the available information include: - Focus on core categories driving growth rather than specific order backlog. - Emphasis on brand building and expansion into new categories and channels. - Growth driven by increased direct distribution and quick commerce channels. - No explicit mention of orderbook size or pending orders in the disclosed discussion. Thus, no quantifiable data on orderbook or pending orders is available in the provided transcript.